Gapping up
In reaction to strong earnings/guidance: SMTC +6.8%, HRL +2%, NM +1.3%, ASM +0.5%, CACI +0.3%.
M&A news: ACT +1.9% (may be a possible takeover target following ending of Pfizer (PFE) and Asterzenca (AZN) takeover talks, according to reports), VMW +1.1% (announced the acquisition of CloudVolumes, a provider of real-time application delivery technology).
Select phrama/biotech related names showing strength: AZN +2.4% (rumored interest in ACT), EXAS +1.4%, SNY +1%, CELG +1%.
Select semi names showing strength: SMTC +6.8%, STM +1.7%, ASML +1.2%.
Other news: UNTK +8.8% (common stock to begin trading on the OTC), DGLY +8.1% (recent momentum body camera play), TKMR +4.6% (seeing early strength; NYTimes positive on experimental drug for ebola-like virus), AUXL +4.5% (announces positive data from Phase 2a study of CCH In patients with cellulite), BLRX +2.9% (announces receipt of Notice of Allowance from USPTO for a patent claiming the use of BL-7010), CPST +2.5% (still checking), HTZ +1.5% (following late move higher in Icahn stake news), PANW +1.3% (positive mention on Mad Money).
Analyst comments: PLAB +4.1% (upgraded to Buy from Hold at Needham), AEO +1.2% (upgraded to Buy at Janney, upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), ROSE +1.1% (upgraded to Accumulate from Hold at KLR Group), CRH +0.8% (upgraded to Mkt Perform from Underperform at Bernstein)
In reaction to strong earnings/guidance: SMTC +6.8%, HRL +2%, NM +1.3%, ASM +0.5%, CACI +0.3%.
M&A news: ACT +1.9% (may be a possible takeover target following ending of Pfizer (PFE) and Asterzenca (AZN) takeover talks, according to reports), VMW +1.1% (announced the acquisition of CloudVolumes, a provider of real-time application delivery technology).
Select phrama/biotech related names showing strength: AZN +2.4% (rumored interest in ACT), EXAS +1.4%, SNY +1%, CELG +1%.
Select semi names showing strength: SMTC +6.8%, STM +1.7%, ASML +1.2%.
Other news: UNTK +8.8% (common stock to begin trading on the OTC), DGLY +8.1% (recent momentum body camera play), TKMR +4.6% (seeing early strength; NYTimes positive on experimental drug for ebola-like virus), AUXL +4.5% (announces positive data from Phase 2a study of CCH In patients with cellulite), BLRX +2.9% (announces receipt of Notice of Allowance from USPTO for a patent claiming the use of BL-7010), CPST +2.5% (still checking), HTZ +1.5% (following late move higher in Icahn stake news), PANW +1.3% (positive mention on Mad Money).
Analyst comments: PLAB +4.1% (upgraded to Buy from Hold at Needham), AEO +1.2% (upgraded to Buy at Janney, upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), ROSE +1.1% (upgraded to Accumulate from Hold at KLR Group), CRH +0.8% (upgraded to Mkt Perform from Underperform at Bernstein)